RARγ Is Required for DNA Damage-Induced Necroptosis and Extrinsic Apoptosis
(A and B) Rarγ+/+ and Rarγ−/− cells were treated with cisplatin (left panels) or etoposide (right panels) for the indicated time. Cell lysates were analyzed by immunoblotting as indicated. See also Figure S2.
(C) Rarγ+/+ and Rarγ−/− cells were treated with cisplatin 50 μM (left panel) or etoposide 50 μM (right panel) for the indicated time period, and cell death analysis was determined by propidium iodide staining and analyzed by flow cytometry. See also Figure S3.
(D) Rarγ+/+, Rarγ−/−, and Rarγ−/− + WT-RARγ cell lysates were analyzed by immunoblotting as indicated (upper panel). Rarγ+/+, Rarγ−/−, and Rarγ−/− + WT-RARγ cells were treated with cisplatin 50 μM (lower left panel) or etoposide 50 μM (lower right panel) for the indicated time period, and cell death analysis was determined by popidium iodide staining and analyzed by flow cytometry.
All blots above are representative of one of three experiments. Results shown are averages ± SEM from three independent experiments. ∗∗p < 0.01, ∗∗∗p < 0.001.